Publicaciones en las que colabora con Ana María Muñoz Patiño (9)

2024

  1. Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson’s disease models

    Stem Cell Research and Therapy, Vol. 15, Núm. 1

2023

  1. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  2. Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia

    Antioxidants, Vol. 12, Núm. 7

  3. The cannabinoid CB1 receptor interacts with the angiotensin AT2 receptor. Overexpression of AT2-CB1 receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats

    Experimental Neurology, Vol. 362

2022

  1. Angiotensin Type-1 Receptor Inhibition Reduces NLRP3 Inflammasome Upregulation Induced by Aging and Neurodegeneration in the Substantia Nigra of Male Rodents and Primary Mesencephalic Cultures

    Antioxidants, Vol. 11, Núm. 2

2021

  1. Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists

    Frontiers in Neuroendocrinology, Vol. 62

  2. Novel Interactions Involving the Mas Receptor Show Potential of the Renin–Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia

    Neurotherapeutics, Vol. 18, Núm. 2, pp. 998-1016

2020

  1. Angiotensin AT1and AT2receptor heteromer expression in the hemilesioned rat model of Parkinson's disease that increases with levodopa-induced dyskinesia

    Journal of Neuroinflammation, Vol. 17, Núm. 1

2016

  1. Effects of rho kinase inhibitors on grafts of dopaminergic cell precursors in a rat model of Parkinson’s disease

    Stem Cells Translational Medicine, Vol. 5, Núm. 6, pp. 804-815